Strive Compounding Pharmacy filed a federal antitrust lawsuit Jan. 14 against Eli Lilly and Novo Nordisk, alleging the two drugmakers used their market power to restrict access to compounded GLP-1 medications and suppress competition.
The lawsuit, filed in the U.S. District Court for the Western District of Texas, claims the companies coordinated a campaign to discourage providers, patients and telehealth platforms from using compounded versions of GLP-1 drugs — injectable medications used to treat diabetes and obesity. Strive said the actions “undermined” the compounding pharmaceutical industry, which serves patients who cannot tolerate or access commercially manufactured products.
The complaint comes amid years of escalating tension between brand-name GLP-1 manufacturers and compounding pharmacies. In late 2024, Novo Nordisk filed a citizen petition with the FDA to block compounded versions of liraglutide. Eli Lilly had previously filed a similar petition targeting compounded GLP-1 receptor agonists.
In early 2025, the FDA directed compounders to halt production of semaglutide-based copycats such as Ozempic and Wegovy after shortages were declared resolved. While many compounders complied, others challenged the FDA’s decision in court or continued to sell modified versions under regulatory loopholes.
Strive’s lawsuit adds to the growing legal and regulatory battles over compounded GLP-1 access. The pharmacy is seeking injunctive relief and damages, arguing the defendants’ conduct violates antitrust laws and endangers patient choice.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
